Company Information
What does MIV Therapeutics do?
MIV Therapeutics is developing a next-generation line of ultra thin, polymer-free passive and drug-eluting coatings for cardiovascular stents and a broad range of other implantable medical devices.
The Company's proprietary ultra-thin, hydroxyapatite (HAp) based polymer-free coating has demonstrated excellent safety and biocompatibility in animal studies and human clinical trials for the Companies first hydroxyapatite based product the VESTAsync™ Coronary Drug Eluting Stent System began in May 2007.
Introduction of new biocompatible polymer-free coatings is expected to provide an attractive alternative to current polymer-based drug-eluting coatings especially in the drug eluting stent market, where it is widely believed that polymers are associated with an increase in undesirable side effects that may be fatal.
